StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL – Free Report) in a research report sent to investors on Wednesday morning. The firm issued a sell rating on the medical technology company’s stock.
A number of other equities analysts also recently weighed in on the stock. Benchmark reaffirmed a speculative buy rating and issued a $0.40 price target on shares of BIOLASE in a research note on Tuesday, May 14th. Maxim Group downgraded shares of BIOLASE from a strong-buy rating to a hold rating in a research note on Friday, May 24th.
Check Out Our Latest Stock Analysis on BIOLASE
BIOLASE Trading Down 7.1 %
BIOLASE (NASDAQ:BIOL – Get Free Report) last posted its quarterly earnings results on Monday, May 13th. The medical technology company reported ($0.36) earnings per share for the quarter. BIOLASE had a negative return on equity of 1,782.73% and a negative net margin of 43.56%. The company had revenue of $10.13 million during the quarter.
Hedge Funds Weigh In On BIOLASE
An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC grew its holdings in BIOLASE, Inc. (NASDAQ:BIOL – Free Report) by 1,068.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 143,537 shares of the medical technology company’s stock after purchasing an additional 131,248 shares during the quarter. Virtu Financial LLC owned about 0.43% of BIOLASE worth $27,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 8.79% of the company’s stock.
BIOLASE Company Profile
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.
Featured Stories
- Five stocks we like better than BIOLASE
- Insider Buying Explained: What Investors Need to Know
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- There Are Different Types of Stock To Invest In
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.